Alector Raises $29.5M in Series D 


What does Alector do?

Alector, is a company which is combining state of the art antibody technology and human genetics and neuroimmunology’s recent discoveries for developing novel therapeutics for Alzheimer’s disease, mechanistically related neurodegenerative disorders and other forms of dementia. The company’s strategy is efficiently generating and validating antibody drugs with unique functional properties which engage key diseases altering targets. The company is currently developing leads for 4 major targets and anticipates taking 2 of these via pre clinical development and IND enabling studies within 2 years. The company has incorporated a highly integrated and lean biotechnology structure with large outsourcing which supports core scientific and management teams.

How much Alector was funded?

Alector raised $29.5M in Series D on January 7, 2016 from Dementia Society.

Previous funding

  • Undisclosed amount in Series A on October 31, 2013 from Polaris Partners and OrbiMed Advisors
  • $32M in Series C on September 16, 2015 from MRL Ventures, Polaris Partners, OrbiMed Advisors, Mission Bay Capital, Topspin Partners and GV.

What is next for Alector?

The company has raised a total of $61.5M to date. The financial resources help the company in independently advancing its promising drug candidates into the clinic and for expanding its discovery pipeline of candidates for neurodegenerative disorders. The company’s next challenge will be the prioritization and partnering strategy across its portfolio.  The financial position provides the company a great optionality and helps the company in controlling its own destiny for the foreseeable future. The company is currently hiring exceptional neurobiologists and immunologists at all levels.

More about Alector

Alector was founded in 2013 by Asa Abeliovich, Tillman Gerngross and Arnon Rosenthal. It has its headquarters in San Francisco, CA. The company is startup which is focused in neurology which is pioneering the discovery and development of 1st in class immunomodulatory therapies for neurodegenerative disorders especially Alzheimer’s diseases